TIDMVAL

ValiRx PLC

13 September 2017

Hardman Research: GeneICE and VAL101 progress

GeneICE and VAL101 progress: ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company's two leading assets are in clinical trials: VAL201 (Phase I/II) - a peptide for advanced prostate cancer and potential to treat other hormone- induced indications; and VAL401 (Phase II) - a novel reformulation of risperidone, in trials for lung cancer. Optimisation of the manufacturing process for its GeneICE technology platform has enabled the development of a commercially viable process and acceleration of the development of VAL101 towards the clinic.

Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/valirx-plc-documents/13.09.17-geneice-and-val101-progress.pdf

 
 To contact us:         Analysts: 
  Hardman & Co           Dr Martin Hall mh@hardmanandco.com 
  35 New Broad Street    Dr Dorothea Hill dmh@hardmanandco.com 
  London                 Dr Gregoire Pave gp@hardmanabdco.com 
  EC2M 1NH               Telephone: +44 20 7194 7622 
                         Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAVXLBFDKFXBBL

(END) Dow Jones Newswires

September 13, 2017 04:34 ET (08:34 GMT)

Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Valirx Charts.
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Valirx Charts.